


SARS Developing a Research Response

- ANTIVIRAL SCREENING PROGRAM
 - USAMRIID/NIAID/CDC
 - ASSAY IS VERO 76 TISSUE CULTURE
 - MODERATE THRUPUT
- NEED: HIGH THRUPUT (LUCIFERASE)
- APPROVED DRUGS, DRUGS IN DEVEL. AND NOVEL COMPOUNDS
- Alpha and beta INTERFERON, RIMANTADINE, CYSTEINE PROTEINASE
- RIBAVIRIN INACTIVE AT >250ug/ml
- MANY OTHER COMPOUNDS, CLASSES UNDER STUDY
- NOVEL MTA/CRADA TO PROTECT SPONSOR INTELLECTUAL PROPERTY






SARS Developing a Research Response

ANIMAL MODELS

- DEVELOPMENT ESSENTIAL
- SOME PROGRESS MADE WITH PRIMATE
- NEED ALSO SMALL (RODENT) ANIMAL
- STUDY MHV FOR RELEVANCE
- DIFFERENT MODELS MAY BE IMPORTANT FOR DIFFERENT QUESTIONS
- AGENTS ACTIVE AGAINST OTHER HUMAN CORONAVIRUSES MAY NOT BE RELEVANT






SARS Developing a Research Response

EXPEDITE DEVELOPMENT PROCESS

- SUPPORT FOR PRECLINICAL STUDIES
- EARLY INVOLVEMENT OF THE FDA
- INCENTIVES FOR PHARMA





SARS Developing a Research Response

UTILIZE CLINICAL TRIAL NETWORKS

- ESTABLISH PROTOCOLS AND MAKE AVAILABLE
- ENHANCE INTERNATIONAL COLLABORATIONS

